Flotral

Flotral Warnings

alfuzosin

Manufacturer:

Sun Pharma

Distributor:

DKLL

Marketer:

Ranbaxy
Full Prescribing Info
Warnings
Special warnings: As with all alpha-1 blockers, some patients, and in particularly those treated with antihypertensives may report postural hypotension within a few hours following administration, possibly with symptoms (dizzy sensations, fatigue, sweating).
If this occurs, patients should remain lying down until the symptoms have completely subsided.
These effects are usually transient, occur at the beginning of treatment and do not generally prevent continued treatment.
Pronounced drop in blood pressure has been reported in post-marketing surveillance in patients with pre-existing risk factors (such as underlying cardiac diseases and/or concomitant treatment with antihypertensive medication). The risk of developing hypotension and related adverse reactions may be greater in elderly patients.
Patients should be warned of the possible occurrence of these events. Care should be taken when alfuzosin is administered to patients with symptomatic orthostatic hypotension or in patients on anti-hypertensive medication or nitrates.
Use with caution in patients with acquired or congenital QT prolongation or who are taking medications that prolong the QT interval.
Alfuzosin, like other alpha-1 blockers, has been associated with priapism (persistent painful penile erection unrelated to sexual activity). Because this condition can lead to permanent impotence if not properly treated, patients should be advised about the seriousness of the condition (see ADVERSE REACTIONS).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in